To rapidly and effectively test vaccines, they must be tested in regions where viral spread and case numbers are high. With Covid19, high incidence has been in groups or countries already marginalised or economically disadvantaged.
If testing in these regions is necessary, then it is critical that protections for the vulnerable are robust and that post approval access to treatments, normally most accessible to those who can pay, are also guaranteed.
This article also highlights the benefits of countries having dedicated and sophisticated clinical trials facilities that are highly skilled in large phase 3 vaccine studies. Certainly missing in our Australian landscape and a real opportunity.